These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34123791)

  • 1. Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy.
    Borghi L; Rosti G; Maggi A; Breccia M; Di Bona E; Iurlo A; La Barba G; Sportoletti P; Albano F; Galimberti S; Rivellini F; Cambrin GR; Capodanno I; Cuneo A; Bonifacio M; Sica S; Arcaini L; Capochiani E; Minotto C; Ciceri F; Crugnola M; Di Caprio L; Supekar S; Elena C; Baccarani M; Vegni E
    Front Oncol; 2021; 11():638689. PubMed ID: 34123791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Myeloid Leukemia Patient's Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial.
    Borghi L; Galimberti S; Baratè C; Bonifacio M; Capochiani E; Cuneo A; Falzetti F; Iurlo A; Lunghi F; Minotto C; Orlandi EM; Rege-Cambrin G; Sica S; Supekar S; Haenig J; Vegni E
    Front Psychol; 2019; 10():329. PubMed ID: 30842749
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
    Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
    Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
    Ross DM; Masszi T; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; Garcia-Gutierrez V; Gattermann N; le Coutre PD; Martino B; Saussele S; Giles FJ; Radich JP; Saglio G; Deng W; Krunic N; Bédoucha V; Gopalakrishna P; Hochhaus A
    J Cancer Res Clin Oncol; 2018 May; 144(5):945-954. PubMed ID: 29468438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.
    Hochhaus A; Masszi T; Giles FJ; Radich JP; Ross DM; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; García-Gutiérrez V; Gattermann N; Wiktor-Jedrzejczak W; le Coutre PD; Martino B; Saussele S; Menssen HD; Deng W; Krunic N; Bedoucha V; Saglio G
    Leukemia; 2017 Jul; 31(7):1525-1531. PubMed ID: 28218239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients.
    Yamazaki K; Inagaki N; Moldaver D; Viana R; Kimura S
    Cancer Sci; 2020 Jul; 111(7):2526-2535. PubMed ID: 32324296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
    JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia.
    Han JJ
    Blood Res; 2023 Apr; 58(S1):S58-S65. PubMed ID: 37026381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy.
    Bonifacio M; Maheshwari V; Tran D; Agostoni G; Filioussi K; Viana R
    Pharmacoecon Open; 2022 Jan; 6(1):95-104. PubMed ID: 34297312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
    Shanmuganathan N; Pagani IS; Ross DM; Park S; Yong ASM; Braley JA; Altamura HK; Hiwase DK; Yeung DT; Kim DW; Branford S; Hughes TP
    Blood; 2021 Mar; 137(9):1196-1207. PubMed ID: 32871588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
    Radich JP; Hochhaus A; Masszi T; Hellmann A; Stentoft J; Casares MTG; García-Gutiérrez JV; Conneally E; le Coutre PD; Gattermann N; Martino B; Saussele S; Giles FJ; Ross DM; Aimone P; Li S; Titorenko K; Saglio G
    Leukemia; 2021 May; 35(5):1344-1355. PubMed ID: 33707652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.
    Hughes TP; Clementino NCD; Fominykh M; Lipton JH; Turkina AG; Moiraghi EB; Nicolini FE; Takahashi N; Sacha T; Kim DW; Fellague-Chebra R; Tiwari R; Bouard C; Mahon FX
    Leukemia; 2021 Jun; 35(6):1631-1642. PubMed ID: 33980976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
    Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.
    Takahashi N; Nishiwaki K; Nakaseko C; Aotsuka N; Sano K; Ohwada C; Kuroki J; Kimura H; Tokuhira M; Mitani K; Fujikawa K; Iwase O; Ohishi K; Kimura F; Fukuda T; Tanosaki S; Takahashi S; Kameoka Y; Nishikawa H; Wakita H;
    Haematologica; 2018 Nov; 103(11):1835-1842. PubMed ID: 29976734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice.
    Aleem A; Shaheen NA; Algahtani F; Jamal A; Alkhudair N; Alghafis M; Iqbal Z; Siti HWZ; Thomas A; Alahmari B; Salama H; Gmati G; Alzahrani M; Alhejazi A; Alfayez M; Alrajhi A; Marei MA; Alaskar A
    Clin Lymphoma Myeloma Leuk; 2024 Aug; ():. PubMed ID: 39299826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon.
    Elias F; Gebran A; Said C; Beker RV; Ammar W
    J Glob Oncol; 2019 Jun; 5():1-7. PubMed ID: 31166826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
    Caldemeyer L; Akard LP
    Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study.
    Yu L; Wang H; Milijkovic D; Huang X; Jiang Q
    BMC Cancer; 2018 Aug; 18(1):782. PubMed ID: 30075760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.